火把花根片治疗面部激素依赖性皮炎疗效观察

目的：观察火把花根片治疗激素依赖性皮炎的疗效和安全性。方法：患者81例，分为治疗组和对照组。对照组：口服氯雷他定片，10mg／次，1次／天，同时外用氧化锌软膏；治疗组：在对照组用药的基础上加服火把花根片，5片／次，3次／天；疗程均为2个月。结果：治疗组总有效率达68．29％，对照组总有效率达24．24％，两组疗效比较有显著性差异（P〈0．01）。结论：火把花根片治疗面部激素依赖性皮炎安全、有效。     

丙氨瑞林治疗子宫内膜癌病人的性激素及有丝分裂指数的变化

目的：观察丙氨瑞林对子宫内膜癌的治疗作用。方法：对诊刮确诊的１７例子宫内膜癌病人，予丙氨瑞林７００μｇ，ｉｍ，ｑｄ×７ｄ，用药前后作性激素测定及组织学检查。结果：绝经妇女用药后血中ＦＳＨ和ＬＨ下降（Ｐ＜０．０１和＜０．０５），雌二醇、孕酮及睾丸酮变化不明显。其中１３例内膜样腺癌用药后有丝分裂指数明显下降（Ｐ＜０．０１），有丝分裂指数变化与癌周内膜之反应有关。呈增生反应癌周内膜癌组织有丝分裂指数下降值明显高于呈萎缩状态癌周内膜。结论：丙氨瑞林治疗子宫内膜癌后能降低ＦＳＨ和ＬＨ水平，对子宫内膜癌尤其是雌激素依赖性内膜癌有一定疗效。     

Epidermal growth factor receptor levels increase but epidermal growth factor receptor ligand levels decrease in mouse mammary tumors during progression from hormone dependence to hormone independence

Summary Twenty-six serially transplanted Grunder (GR) strain mouse mammary tumors were analyzed for epidermal growth factor receptor (EGFR) and EGFR-ligand levels, in addition to steroid hormone receptors (estrogen receptor, ER, progesterone receptor, PgR). In concordance with earlier studies, hormone dependent (HD) and hormone responsive (HR) tumors were found to be positive for both ER and PgR, whereas hormone independent (HI) tumors contained only 30% of the ER concentration that was found in the HD tumors. PgR was undetectable in HI tumors. HI tumors contained 2.5 to 3-fold higher EGFR levels than HD/HR tumors, an observation which shows remarkable concordance with studies on EGFR in human breast cancer. On the other hand, the level of EGFR-ligand(s) was positively associated with ER levels and was three-fold higher in HD/HR tumors than in HI tumors. The low EGFR in HD/HR tumors relative to HI tumors may be the result of downregulation by EGFR ligands produced under ER control. During progression to hormone independence this downregulation of EGFR is then abolished in absence of ER. The increase in EGFR may therefore be a secondary effect rather than a key event in the progression to hormone independence in this mouse mammary tumor model.Abbreviations EGF Epidermal Growth Factor - EGFR Epidermal Growth Factor Receptor - ER Estrogen Receptor - PgR Progesterone Receptor - HD Hormone Dependent - HR Hormone Responsive - HI Hormone Independent - HAP Hydroxylapatite - DCC Dextran Coated Charcoal - GR Grunder - TGF- Transforming Growth Factor-     

3,4-Bis(3′-hydroxyphenyl)hexane — A new mammary tumor-inhibiting compound

Summary The syntheses of the hexestrol derivatives 3,4-bis-(3-hydroxyphenyl)hexane (4a), 3,4-bis(4-fluoro-3-hydroxyphenyl)hexane (4b), 3,4-bis(3, 4dihydroxyphenyl)hexane (4c), and 3,4-bis(3,4-diacetoxyphenyl)hexane (4d) are described. All compounds showed a marked, competitive inhibition of the estradiol receptor interaction (K _a4c>K_a4a>K_a4d>K_a4b). Evaluated in the mouse uterine weight test compounds 4c and 4d almost reached the estrone effect, whereas 4a and 4b did not produce full uterotrophic response. Compounds 4a-d antagonized the estrone stimulated uterine growth of the immature mouse. Compound 4a (NSC-297170) exhibited a specific, dose-related growth inhibition of the estrogen responsive MCF-7 human breast tumor cell line. Tested on the 9,10-dimethyl-1,2-benzanthracene-induced hormonedependent mammary adenocarcinoma of the Sprague-Dawley rat all compounds showed marked inhibition of tumor growth. As in all experiments compounds 4a and 4b, which is resistant to hydroxylation in 4position exhibited an identical pattern of action, which is different from that shown by compound 4c, the effect of compound 4a cannot be explained by its possible catechol metabolite 4c.Supported by grants from the Deutsche Forschungsgemeinschaft and the Verband der Chemischen Industrie-Fonds der Chemischen Industrie     

重组牛碱性成纤维细胞生长因子联合他克莫司软膏治疗面部激素依赖性皮炎的有效性和安全性

目的 探讨重组牛碱性成纤维细胞生长因子联合他克莫司软膏治疗面部激素依赖性皮炎的有效性及安全性.方法 选取2018年10月至2020年10月我院皮肤科收治的80例面部激素依赖性皮炎患者作为研究对象,按照随机数表法将其分为对照组与观察组,每组40例.对照组采用他克莫司软膏治疗,观察组采用他克莫司软膏治联合重组牛碱性成纤维细...     

中西医结合治疗激素依赖性肾病综合征疗效观察

目的:探讨中西医结合治疗激素依赖性肾病综合征的临床疗效。方法:将患者随机分为治疗组和对照组观察临床疗效。治疗组以中西医结合(即根据激素应用的不同阶段加用中药)治疗,对照组以单纯西药(激素强的松口服)治疗,观察临床缓解率、复发率和不良反应率。结果:治疗组30例,总有效率为90%,对照组28例,总有效率为67.9%,有显著性差异;治疗组0.5年、1年、2年的复发率分别为0、4.5%、9.1%,对照组为8.3%、25%、41.7%;治疗组不良反应发生率为36.7%,对照组为92.9%。结论:中西医结合治疗激素依赖性肾病综合征相得益彰,疗效明显优于单纯应用西药激素者,且减少复发率和不良反应。     

Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men

PURPOSE: Herbal remedies high in phytoestrogens have been shown to reduce serum prostate specific antigen (PSA) and have been proposed as a treatment for prostate cancer. Soy proteins used to lower serum cholesterol are rich sources of phytoestrogens. Therefore, we assessed the effect of soy consumption on serum PSA in men who had participated in cholesterol lowering studies. MATERIALS AND METHODS: For 3 to 4 weeks 46 healthy middle-aged men with a range of starting PSA values took soy (mean 44 gm. soy protein daily, 116 mg. isoflavones daily) or control foods, and a subgroup of men took a lower level of soy supplements for 3 months. PSA was measured at the start and end of each treatment. RESULTS: Soy had no significant effect on serum total or free PSA, independent of PSA starting value or isoflavone intake. The lack of effect on PSA was seen, although soy intake was sufficient to reduce low-density lipoprotein cholesterol (5.8 +/- 2.2%, p = 0.012), the estimated coronary heart disease risk (6.1 +/- 2.8% for 10 years, p = 0.032) and the serum concentration of oxidized low-density lipoprotein measured as conjugated dienes (9.5 +/- 3.4%, p = 0.008) in the 3 to 4-week study. In addition, the lack of effect of soy on PSA persisted for the 3 months of the extended study. CONCLUSIONS: At levels of soy intake which reduce low-density lipoprotein cholesterol any potential benefits of soy consumption on prostate cancer are likely to occur for reasons other than alterations in hormone activity.     

Luteinizing hormone-releasing hormone antagonists

Background: Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications. Objective/method: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications. Recently patented compounds as well as drug formulations and dosage are presented. Conclusion: LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.     

Aromatase inhibitors for breast cancer: pharmacoeconomic considerations

Although the anti-oestrogen tamoxifen is recognised as the treatment of choice for both premenopausal and postmenopausal women with advanced hormone-dependent breast cancer, oestrogen deprivation can also be achieved, with apparently less adverse-effects, through selective inhibition of aromatase. Recent clinical trials have demonstrated the efficacy and tolerability of the new generation of aromatase inhibitors as second-line and first-line therapy in postmenopausal women with breast cancers who were eligible for endocrine treatment. Speculating that administration of aromatase inhibitors will not be limited to postmenopausal breast cancer, a pharmacoeconomic perspective is considered based on available data and putative therapeutic application during various phases of the disease.     

中西医结合治疗面部激素依赖性皮炎疗效观察

目的:观察中西医结合治疗面部激素依赖性皮炎的效果。方法:将278例面部激素依赖性皮炎患者随机分成治疗组142例和对照组136例。对照组单独用氯雷他定片抗过敏及对症治疗,治疗组在此基础上加用中药口服和外敷等治疗。结果:治疗组总有效率为85.21%,对照组为63.97%,两组比较差异有统计学意义(P<0.01)。结论:中西医结合治疗面部激素依赖性皮炎疗效较好,无毒副作用。